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AbstrACt
Objectives Randomised controlled trials in healthcare 
increasingly include economic evaluations. Some show 
small differences which are not statistically significant. 
Yet these sometimes come to paradoxical conclusions 
such as: ‘the intervention is not clinically effective’ but 
‘is probably cost- effective’. This study aims to quantify 
the extent of non- significant results and the types of 
conclusions drawn from them.
Design Cross- sectional retrospective analysis of 
randomised trials published by the UK’s National 
Institute for Health Research (NIHR) Health Technology 
Assessment programme. We defined as ‘doubly null’ 
those trials that found non- statistically significant 
differences in both primary outcome and cost per 
patient. Paradoxical was defined as concluding in favour 
of an intervention, usually compared with placebo or 
usual care. No human participants were involved. Our 
sample was 226 randomised trial projects published by 
the Health Technology Assessment programme 2004 to 
2017. All are available free online.
results The 226 projects contained 193 trials with a 
full economic evaluation. Of these 76 (39%) had at least 
one ‘doubly null’ comparison. These 76 trials contained 
94 comparisons. In these 30 (32%) drew economic 
conclusions in favour of an intervention. Overall report 
conclusions split roughly equally between those 
favouring the intervention (14), and those favouring 
either the control (7) or uncertainty (9).
Discussion Trials with ‘doubly null’ results and 
paradoxical conclusions are not uncommon. The 
differences observed in cost and quality- adjustedlife 
year were small and non- statistically significant. Almost 
all these trials were also published in leading peer- 
reviewed journals. Although some guidelines for reporting 
economic results require cost- effectiveness estimates 
regardless of statistical significance, the interpretability 
of paradoxical results has nowhere been addressed.
Conclusions Reconsideration is required of the 
interpretation of cost- effectiveness analyses in 
randomised controlled trials with ‘doubly null’ 
results, particularly when economics favours a novel 
intervention.
bACkgrOunD
Randomised trials are widely seen as 
providing the most robust evidence of the 
effectiveness of healthcare interventions. 
For that reason, they are mandatory for drug 
licensing. Many trials show null results, that is 
a non- statistically significant difference in the 
primary outcome. Several studies have identi-
fied ‘spin’ whereby authors nonetheless draw 
possibly unwarranted conclusions.1–3
Given the importance of costs, trials increas-
ingly include estimation of cost- effectiveness. 
Even when both outcome and cost show only 
small, non- significant differences, some trials 
make strong claims. Apparently paradoxical 
conclusions are sometimes drawn along the 
lines that ‘the intervention was not clinically 
effective’ but ‘is probably cost- effective’.
The definition of ‘spin’ relies largely on 
statistical significance, a concept which some 
have seen as outdated.4 Economic evaluation 
in randomised trials has abandoned statistical 
significance in favour of decision analysis.5 
strengths and limitations of this study
 ► A strength of this study is the identification of a 
problem to do with results on cost- effectiveness 
from randomised trials which is fairly common but 
has not otherwise been reported or examined.
 ► A limitation was that the sample was confined 
to that of trials funded and published by the UK’s 
Health Technology Assessment (HTA) programme.
 ► The study was strengthened by using full reports 
of each study in the HTA monograph series, which 
requires conclusions and recommendations for 
research.
 ► The generalisability of this study was enhanced by 
the fact that most of the trials reviewed were pub-
lished in major peer- reviewed medical journals.
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Figure 1 Flowchart: projects including randomised trials identifying those which included a ‘doubly null’ result.
This new approach has become the norm, as reflected 
in guidelines for reporting such as CHEERS (Consol-
idated Health Economics Evaluation Reporting state-
ment).6 Most trials however continue to be designed to 
test hypotheses using statistical significance7 not least due 
to drug licensing requirements.8
Claims that a new intervention is cost- effective usually 
imply that it should be adopted. Claims to the contrary, 
in favour of placebo or usual care, by contrast imply no 
change. Our interest has mainly to do with the former 
due to the implications for healthcare.
We defined as ‘doubly null’ those trials that found 
no statistically significant difference in both primary 
outcome and cost per patient. Paradoxical was defined 
as going on to conclude in favour of an intervention, 
whether compared with placebo, usual care or to another 
intervention.
We aimed to establish how often ‘doubly null’ results 
occur and how commonly paradoxical conclusions were 
drawn. Our sample was randomised trials funded and 
published by the UK National Health Service (NHS). 
The NHS funds research through National Institute 
for Health Research (NIHR). Its largest programme, 
the Health Technology Assessment (HTA) programme 
mainly funds systematic reviews and randomised trials. 
Those trials usually include economic evaluation. The 
programme publishes the entire findings of each trial 
in its monograph series. These combine reports of clin-
ical efficacy, cost and cost- effectiveness in a format that 
requires an overall conclusion.9
MethODs
The criteria for trials with ‘doubly null’ results were non- 
statistically significant differences in both (a) the primary 
outcome, and (b) mean cost per patient. Significance was 
defined at the 0.05 level (or 95% CIs).
Our sampling frame was all 226 projects which 
included a randomised trial published by the NIHR HTA 
programme 2004 to 2017. We then excluded three types 
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Table 1 Projects containing randomised trials published 
by National Institute for Health Research Health Technology 
Assessment programme 2004 to 2017, by those with 
‘doubly null’ results and conclusions drawn
Volume Year
RCTs 
(n)
Doubly 
null (n) % Comparisons
8 2004 8 1 12.5 1
9 2005 13 6 46.2 8
10 2006 9 3 33.3 4
11 2007 8 1 12.5 1
12 2008 3 1 33.3 1
13 2009 16 7 43.8 10
14 2010 11 5 45.5 6
15 2011 8 0 0.0 0
16 2012 8 7 87.5 8
17 2013 11 7 63.6 10
18 2014 17 10 58.8 15
19 2015 28 13 46.4 14
20 2016 27 11 40.7 11
21 2017 26 4 15.4 5
193 76 39.4 94
The 76 trials contained 94 comparisons (table 1). This was due to 
some trials having several arms.
RCTs, Randomised controlled trials.
of trials: those testing non- inferiority, those which did 
not report an economic evaluation and those which were 
stopped prematurely.
This study did not have an original protocol. It evolved 
from an initial cross- sectional review of ‘doubly null’ 
results to consideration of the implications of paradoxical 
conclusions. This led to preparation of focussed summa-
ries of each trial with such conclusions. All the reports 
reviewed are available free at https://www. journalsli-
brary. nihr. ac. uk/ hta/#/. The volume and issue numbers 
in online supplementary appendix 1 identify all those 
included and those with ‘doubly null’ results.
Monograph titles were used to identify those containing 
a randomised trial. Each trial was checked to identify 
those with ‘doubly null’ results. For each of these, the 
abstract was extracted along with additional text to do 
with cost- effectiveness. Only primary comparisons were 
included, as defined by each project. Overall conclusions 
were classified based on the conclusion section of the 
Abstract. Quotes from those whose economic conclusion 
favoured an intervention are provided in online supple-
mentary appendix 2.
Eligibility and data extraction were carried out by JR 
with independent checks by two researchers (SB, ABJ) 
Disagreements were resolved by discussion with reference 
to the extracts, with additional text extracted if necessary. 
Extracts were stored in Word and analysed in Excel.
Patient and public involvement
There was no patient or public involvement in this project.
results
Our exclusion criteria reduced the number of trial proj-
ects from 226 to 193. Twenty- one projects did not include 
economic evaluation, six were closed early and six were 
non- inferiority trials (figure 1).
Of the 193 trials which included economic evalua-
tion, 76 (39%) had ‘doubly null’ results for at least one 
comparison. These are identified in online supplemen-
tary appendix 1. This proportion varied widely by year 
(table 1).
The economic analyses of these results (table 2) found 
an intervention to have an acceptable incremental cost- 
effectiveness ratio in 30 instances (30/94, 32%).
Project reports with economics analyses supporting an 
intervention came to overall conclusions as stated in their 
abstracts that split roughly equally between favouring 
the intervention (14 comparisons), and those favouring 
either the control (7 comparisons) or uncertainty (9 
comparisons) (figure 2).
Differences in all effect sizes were small. Differences 
in the primary outcome were all less than any prespeci-
fied minimally important difference. None of the quality- 
adjustedlife year (QALY) differences were statistically 
significant. Both cost and QALY differences were very 
small.
The probability of an intervention being cost- effective 
was only loosely associated with the conclusion drawn. 
Those favouring the intervention had on average 89% 
probability of being cost- effective, compared with 79% 
for those favouring a control (see online supplemen-
tary appendix 2). These averages however spanned wide 
ranges and are based on relatively few studies. Some proj-
ects found small differences convincing while others saw 
them as indicating lack of evidence. Other factors such as 
secondary outcomes, borderline significance and patient 
convenience were sometimes mentioned as having influ-
enced the overall conclusions.
DisCussiOn
The potential for drawing conclusions from ‘doubly null’ 
results arises due to different methodological perspec-
tives that can be described as hypothesis testing versus 
decision analysis. Rejection of a hypothesis of superiority 
precludes any conclusion other than the null hypothesis. 
Decision analysts by contrast estimate an acceptable incre-
mental cost per QALY regardless of the size or the statis-
tical significance of differences in cost and outcome.5 CIs 
are replaced by the probability that an intervention is 
cost- effective relative to some threshold such as that asso-
ciated with National Institute for Health and Care Excel-
lence (NICE).
Limitations on our analysis include reliance on a 
possibly atypical sample. However, decision analysis as 
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Table 2 “Doubly null” comparisons: those with economics pro an intervention by overall conclusion
Volume Year
Comparisons Overall conclusions pro:
Comparisons
Economics pro an 
intervention Control Intervention Mixed/uncertain
8 2004 1 1 1
9 2005 8 5 1 2 2
10 2006 4 1 1
11 2007 1 0
12 2008 1 0
13 2009 10 1 1
14 2010 6 2 2
15 2011 0 0
16 2012 8 1 1
17 2013 10 2 2
18 2014 15 6 5 1
19 2015 14 3 1 2
20 2016 11 6 4 2
21 2017 5 2 1 1
  94 30 7 14 9
Economics pro intervention (%) 32%
Overall conclusion (%) 23% (7/30) 47% (14/30) 30% (9/30)
opposed to hypothesis testing has become the recom-
mended approach in guidelines for economic evalua-
tion. The widely used CHEERS guideline6 for reporting 
economic results requires that uncertainty be character-
ised and that:
Because failure to reject the hypothesis about the 
equality of two therapies is not the same as finding 
that outcomes of two therapies are identical, cost- 
effectiveness analysis should still be performed if the 
clinical study fails to demonstrate a statistically signif-
icant difference in clinical end points.6
Journals that have adopted CHEERS may not have 
understood that they were thereby requiring decision 
analysis which would in turn lead to paradoxical conclu-
sions of the sort described here.
Another limitation was that we included some compar-
isons of one intervention against another as opposed to 
a placebo or usual care. This increases the number of 
comparisons that favour an intervention. Against this, 
most trials compared interventions with placebo or usual 
care.
Many of the inter intervention comparisons included 
were all to do with surgery, where interventions were 
commonly used procedures as chosen by the participating 
surgeon. In such comparisons, a conclusion in favour of 
either was deemed paradoxical.
Most of the trials reviewed were also published else-
where. Of the 24 trials with ‘doubly null’ results published 
in HTA monographs in 2015 and 2016 all but one were 
also published in reputable medical peer- reviewed 
journals. However, since clinical and economical results 
could be reported in different articles, the extent of para-
doxical conclusions may not have been apparent.
Our results contribute to the debate over the value 
of a hypothesis testing not least by showing that non- 
significant differences are almost always very small. 
Although authorities such as the American Statistical 
Association4 have urged abandonment of statistical signif-
icance, some prominent medical statisticians have argued 
that by dropping prespecified significance, interpretation 
could become completely arbitrary.8
The monograph reports with ‘doubly null’ results that 
came to conclusions favouring an intervention rarely 
discussed the plausibility of those claims. Research recom-
mendations, which are required in HTA monographs, 
never proposed researching the plausibility of the seem-
ingly paradoxical conclusions.
While trials with non- statistically significant results 
can contribute to knowledge through inclusion in meta- 
analysis, no similar aggregation is possible with estimates 
of cost- effectiveness. To be useful, trial reports should 
include full data on costs and effects along with joint 
uncertainty.
The practice of economic evaluation alongside every 
randomised trial deserves reconsideration. Rather than 
being based on a single trial, economic evaluation should 
generally be based on the totality of evidence estab-
lished by systematic reviews and meta- analysis. NICE and 
similar decision- making bodies specify such methods. 
Only exceptionally (first or biggest trial) can a single trial 
provide grounds for implementation.
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Figure 2 Types of overall conclusions drawn from comparisons which were “doubly null”.
COnClusiOns
‘Doubly null’ results and paradoxical conclusions are 
increasingly drawn from randomised trials of health-
care interventions. In our cohort, almost 40% of trials 
had ‘doubly null’ results . From those whose economic 
evaluation favoured the intervention, projects’ overall 
conclusions split roughly equally between those favouring 
the intervention, and those favouring the control or 
uncertainty.
The possibility of paradoxical conclusions arises from 
different paradigms which are unlikely to change. Trials 
seem likely to continue to be powered on target differ-
ences.7 Decision analysis is required in widely used guide-
lines for reporting economic evaluations.
Editors of journals reporting randomised trials should 
be more alert to the issue of paradoxical conclusions. 
Besides noting them, the plausibility of the conclusions 
need to be questioned. Further research may sometimes 
be required.
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